Issue 8 2019

CEO MONTHLY / ISSUE 8 2019 5 , The OXIS Energy Lithium-Sulfur battery cell technology offers significant benefits to aviation and as a result, it is collaborating with Bye Aerospace of Denver, Colorado to produce a common Li-S ad- vanced battery cell for the high voltage battery pack system to be considered for Bye’s future electric aircraft. These cells will achieve the higher energy densi- ty required for such aircraft. The project will commence in Septem- ber 2019. Huw Hampson-Jones, CEO OXIS Energy, said, “Aviation is one of OXIS’ target markets, and in the first instance, Regional Rapid Air Taxi Transportation. A key meas- ure of OXIS’ suitability is to be able to consistently produce cells in excess of 400 Wh/kg, which are already undergoing evalua- tion. OXIS expects to achieve 500 Wh/kg by early 2020. Our Li-S cells and battery systems are ide- ally suited for aviation. They are over 50% lighter than the current Li-ion cell and battery systems, with the winning formula of a high energy cell at the power required. The use of the same cell format across batteries will also help our customers to minimise cost and improve serviceability.” George Bye, CEO of Bye Aer- ospace, said, “New Li-S battery cells from Oxis have the potential to greatly enhance the quality, cost and performance of eFlyer 4 and our other future aircraft pro- jects. Our collaboration with OXIS is separate from the current eFly- er 2 agreements and intentions we have with confirmed and our future supply chain partners. Bye Aerospace is working with Oxis on the Li-S battery cell character- istics to significantly improve our eFlyer 4 and future air taxi air- craft designs’ performance. The average age of the global market for Turboprop fleet is 28 years. OXIS has the potential to provide a Li-S battery cell that is truly a game-changer.” In ground tests in Europe, OXIS has already shown that Li-S has demonstrated a significant im- provement in simulated flight duration compared with Lithium NMC; it will now undertake a further series of tests which will provide a robust indication of the OXIS Li-S performance. Over the next 18 months, the aim is to move towards the production of commercial cells and battery systems in order to meet the vol- ume roll-out criteria set by Bye Aerospace. OXIS Energy to Develop Proof-of- Concept Advanced, Lightweight Lithium Sulfur Cells for BYE AEROSPACE Companies Launch Phase 1 of Collaboration Programme Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the launch of its first products in the United Kingdom. Neuraxpharm also announces the appointment of new General Manager Craig Bowen, who will run Neuraxpharm UK Ltd., based in Reading (Berkshire, UK). Neuraxpharm UK plans to launch differentiated and specialty generics in the UK, one of the biggest markets in Europe. The UK’s CNS pharmaceutical market represents 11% of the total CNS market in Europe which is valued at GBP 2.9 bn (EUR 3.2 bn). Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm said: “Establishing a strong presence in the UK will enable us to build on our position as a CNS specialist in Europe offering consumer healthcare products, standard generics and added value medicines. We are very pleased to welcome Craig to the Neuraxpharm team. His proven track record of launching new pharmaceutical products will be of great advantage in bringing differentiated products to local patients and healthcare professionals in the UK, one of the top five markets in Europe.” With over 20 years of experience in the pharmaceutical industry, Craig Bowen is an expert in Sales & Business strategy management and offers an extensive knowledge of the UK and Irish markets. Before joining Neuraxpharm UK, Craig was Associate Director and Commercial Head for UK and Ireland in Par Laboratories where he led the creation and initial set up of the Par affiliate in the UK and implemented the commercial strategy to launch Par products into the UK, EU and other international markets. Prior to Par Laboratories, Craig held senior positions in multinational pharmaceuticals companies such as Sanofi Group, Flynn Pharma and Dr. Reddy’s. Previously he worked for more than 10 years in Mylan Pharmaceuticals, where he was Head of UK Sales Operation, responsible for the UK & Ireland sales and commercial departments and focused on creating major new business streams for the company. Craig holds UK higher education qualifications in Business & Finance Management from Coleg Glan Hafren in Cardiff, Wales. Neuraxpharm strategy is to build on its position as a CNS specialist in Europe offering consumer healthcare products, standard generics and added value medicines. Neuraxpharm is investing in its pipeline by developing differentiated and high-tech barrier products in CNS to be commercialised across Europe, now including the UK. The UK launch follows recent Neuraxpharm’s expansion in Eastern Europe through the acquisition of Farmax and an expansion to Poland.